Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)

Medicine and Dentistry

• Body Mass Index 16%
• Combination Therapy 8%
• COVID-19 100%
• Disease Activity 16%
• Disease Course 8%
• Inflammatory Bowel Disease 58%
• Interim Analysis 100%
• Logistic Regression Analysis 8%
• Nosology 8%
• Patient with Inflammatory Bowel Disease 100%
• Symptom 8%
• Tumor Necrosis Factor Antibody 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 8%
• Coronavirinae 100%
• Disease 100%
• Disease Activity 16%
• Disease Classification 8%
• Disease Course 8%
• Inflammatory Bowel Disease 100%
• Remission 8%
• Symptom 8%
• Tumor Necrosis Factor Antibody 8%
• Vaccination Policy 8%

Keyphrases

• Conductor-like Screening Model for Real Solvents (COSMO-RS) 100%